ANAPC11

Summary

ANAPC11 (anaphase promoting complex subunit 11, HGNC:14452) is a protein-coding gene on chromosome 17q25.3, encoding Anaphase-promoting complex subunit 11 (Q9NYG5). Together with the cullin protein ANAPC2, constitutes the catalytic component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. It is a common-essential gene (DepMap: required in 99.7% of cancer cell lines).

Enables cullin family protein binding activity and ubiquitin-ubiquitin ligase activity. Contributes to ubiquitin-protein transferase activity. Involved in anaphase-promoting complex-dependent catabolic process; positive regulation of mitotic metaphase/anaphase transition; and protein polyubiquitination. Located in nucleolus and nucleoplasm. Part of anaphase-promoting complex.

Source: NCBI Gene 51529 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 28 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.7% of screened cell lines (common-essential)
• MANE Select transcript: NM_001002248

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14452
Approved symbol	ANAPC11
Name	anaphase promoting complex subunit 11
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	HSPC214, APC11, Apc11p, MGC882
Ensembl gene	ENSG00000141552
Ensembl biotype	protein_coding
OMIM	614534
Entrez	51529

Gene structure

Transcript identifiers

Ensembl transcripts: 62 — 61 protein_coding, 1 retained_intron

ENST00000344877, ENST00000357385, ENST00000392376, ENST00000571024, ENST00000571570, ENST00000571874, ENST00000572639, ENST00000572851, ENST00000573956, ENST00000574924, ENST00000575195, ENST00000577425, ENST00000577747, ENST00000578544, ENST00000578550, ENST00000579133, ENST00000579978, ENST00000582222, ENST00000583839, ENST00000584197, ENST00000584314, ENST00000585259, ENST00000612413, ENST00000877740, ENST00000877741, ENST00000877742, ENST00000877743, ENST00000877744, ENST00000877745, ENST00000877746, ENST00000877747, ENST00000877748, ENST00000877749, ENST00000926462, ENST00000926463, ENST00000926464, ENST00000926465, ENST00000926466, ENST00000926467, ENST00000926468, ENST00000926469, ENST00000926470, ENST00000926471, ENST00000926472, ENST00000926473, ENST00000926474, ENST00000926475, ENST00000926476, ENST00000926477, ENST00000926478, ENST00000926479, ENST00000926480, ENST00000926481, ENST00000926482, ENST00000926483, ENST00000926484, ENST00000926485, ENST00000926486, ENST00000926487, ENST00000926488, ENST00000926489, ENST00000954122

RefSeq mRNA: 12 — MANE Select: NM_001002248 NM_001002244, NM_001002245, NM_001002246, NM_001002247, NM_001002248, NM_001002249, NM_001289414, NM_001289415, NM_001289416, NM_001289417, NM_001289420, NM_016476

CCDS: CCDS11789, CCDS32769

Canonical transcript exons

ENST00000344877 — 4 exons

Exon	Start	End
ENSE00001511622	81893552	81893614
ENSE00001670164	81894467	81894586
ENSE00002662386	81899920	81900255
ENSE00002713848	81891723	81891841

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 75.5321 / max 617.1914, expressed in 1826 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163373	67.5173	1825
163374	4.0718	1353
163376	2.0418	944
163375	1.2635	762
208457	0.6377	356

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	98.94	gold quality
left testis	UBERON:0004533	98.93	gold quality
apex of heart	UBERON:0002098	98.54	gold quality
temporal lobe	UBERON:0001871	98.48	gold quality
amygdala	UBERON:0001876	98.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.47	gold quality
heart left ventricle	UBERON:0002084	98.40	gold quality
gastrocnemius	UBERON:0001388	98.35	gold quality
right atrium auricular region	UBERON:0006631	98.27	gold quality
substantia nigra	UBERON:0002038	98.24	gold quality
stromal cell of endometrium	CL:0002255	98.21	gold quality
anterior cingulate cortex	UBERON:0009835	98.18	gold quality
putamen	UBERON:0001874	98.08	gold quality
testis	UBERON:0000473	98.07	gold quality
prefrontal cortex	UBERON:0000451	98.03	gold quality
nucleus accumbens	UBERON:0001882	97.97	gold quality
Ammon’s horn	UBERON:0001954	97.96	gold quality
heart	UBERON:0000948	97.94	gold quality
caudate nucleus	UBERON:0001873	97.89	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.88	gold quality
cerebral cortex	UBERON:0000956	97.87	gold quality
frontal cortex	UBERON:0001870	97.84	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.83	gold quality
mucosa of transverse colon	UBERON:0004991	97.82	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.80	gold quality
hypothalamus	UBERON:0001898	97.79	gold quality
lower esophagus	UBERON:0013473	97.79	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.77	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.77	gold quality
left coronary artery	UBERON:0001626	97.71	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-6	yes	21.60
E-CURD-122	yes	17.03
E-MTAB-8559	no	1005.70
E-GEOD-93593	no	6.89
E-CURD-88	no	3.83
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

16 targeting ANAPC11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-505-3P	99.19	69.71	896
HSA-MIR-1261	98.62	68.10	896
HSA-MIR-338-3P	98.14	67.38	1137
HSA-MIR-4518	98.12	66.82	1030
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-1266-5P	97.71	66.92	1052
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-6869-5P	97.17	67.06	634
HSA-MIR-6823-5P	96.26	65.69	919

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 7)

• APC2 Cullin protein and APC11 RING protein comprise the minimal ubiquitin ligase module of the anaphase-promoting complex. (PMID:11739784)
• Inhibition of APC11 function by H(2)O(2) contributes to the delay in cell cycle progression through mitosis that is characteristic of cells subjected to oxidative stress (PMID:15256223)
• Studies indicate that APC/C(Cdh1) is required to maintain genomic stability. (PMID:19826416)
• The authors showed, in vitro, a direct interaction between Orf virus anaphase promoting complex regulator and APC2 and its interference with interactions between APC11 and APC2. (PMID:20826619)
• siRNA targeted against Apc11 could hamper entry into G2/M phase. (PMID:23007976)
• Overexpression of APC11 is correlated with chromosomal instability in colorectal cancer. An association is observed between APC11 expression and lymphovascular invasion and residual tumor. High levels of APC11 protein in primary colorectal tumors is specifically correlated with metastasis at diagnosis. (PMID:29743633)
• The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer. (PMID:37573356)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	anapc11	ENSDARG00000102531
mus_musculus	Anapc11	ENSMUSG00000025135
rattus_norvegicus	Anapc11	ENSRNOG00000036686
drosophila_melanogaster	lmgA	FBGN0250903
caenorhabditis_elegans		WBGENE00000145

Paralogs (2): RBX1 (ENSG00000100387), RNF7 (ENSG00000114125)

Protein

Protein identifiers

Anaphase-promoting complex subunit 11 — Q9NYG5 (reviewed: Q9NYG5)

Alternative names: Cyclosome subunit 11, Hepatocellular carcinoma-associated RING finger protein

All UniProt accessions (5): A0A087X1B5, Q9NYG5, J3KSK3, J3QL35, J3QS46

UniProt curated annotations — full annotation on UniProt →

Function. Together with the cullin protein ANAPC2, constitutes the catalytic component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of ‘Lys-11’-linked polyubiquitin chains and, to a lower extent, the formation of ‘Lys-48’- and ‘Lys-63’-linked polyubiquitin chains. The APC/C complex catalyzes assembly of branched ‘Lys-11’-/‘Lys-48’-linked branched ubiquitin chains on target proteins. May recruit the E2 ubiquitin-conjugating enzymes to the complex.

Subunit / interactions. The mammalian APC/C is composed at least of 14 distinct subunits ANAPC1, ANAPC2, CDC27/APC3, ANAPC4, ANAPC5, CDC16/APC6, ANAPC7, CDC23/APC8, ANAPC10, ANAPC11, CDC26/APC12, ANAPC13, ANAPC15 and ANAPC16 that assemble into a complex of at least 19 chains with a combined molecular mass of around 1.2 MDa; APC/C interacts with FZR1 and FBXO5. Interacts with the cullin domain of ANAPC2. Interacts with UBE2D2.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed at high levels in skeletal muscle and heart; in moderate levels in brain, kidney, and liver; and at low levels in colon, thymus, spleen, small intestine, placenta, lung and peripheral blood leukocyte.

Post-translational modifications. Auto-ubiquitinated.

Domain organisation. The RING-type zinc finger domain coordinates an additional third zinc ion.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the RING-box family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NYG5-1	1	yes
Q9NYG5-2	2

RefSeq proteins (12): NP_001002244, NP_001002245, NP_001002246, NP_001002247, NP_001002248, NP_001002249, NP_001276343, NP_001276344, NP_001276345, NP_001276346, NP_001276349, NP_057560 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR024991	RING-H2_APC11	Domain
IPR051031	RING-box_E3_Ubiquitin_Ligase	Family

Pfam: PF12861

UniProt features (40 total): binding site 12, mutagenesis site 12, strand 9, turn 2, helix 2, chain 1, zinc finger region 1, splice variant 1

Structure

Experimental structures (PDB)

23 structures.

PDB	Method	Resolution (Å)
4R2Y	X-RAY DIFFRACTION	1.75
5JG6	X-RAY DIFFRACTION	2
9GAW	ELECTRON MICROSCOPY	2.9
6Q6G	ELECTRON MICROSCOPY	3.2
6Q6H	ELECTRON MICROSCOPY	3.2
8PKP	ELECTRON MICROSCOPY	3.2
5G05	ELECTRON MICROSCOPY	3.4
8TAU	ELECTRON MICROSCOPY	3.5
4UI9	ELECTRON MICROSCOPY	3.6
6TNT	ELECTRON MICROSCOPY	3.78
6TLJ	ELECTRON MICROSCOPY	3.8
5G04	ELECTRON MICROSCOPY	3.9
6TM5	ELECTRON MICROSCOPY	3.9
9N9R	ELECTRON MICROSCOPY	3.9
9N9S	ELECTRON MICROSCOPY	3.9
8TAR	ELECTRON MICROSCOPY	4
5LCW	ELECTRON MICROSCOPY	4.2
5A31	ELECTRON MICROSCOPY	4.3
5KHU	ELECTRON MICROSCOPY	4.8
5KHR	ELECTRON MICROSCOPY	6.1
5L9T	ELECTRON MICROSCOPY	6.4
5L9U	ELECTRON MICROSCOPY	6.4
2MT5	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYG5-F1	92.56	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (12): 58; 59; 73; 76; 23; 26; 34; 37; 44; 51; 53; 56

Mutagenesis-validated functional residues (12):

Position	Phenotype
23	greatly reduces autoubiquitination activity; in isoform 1.
26	greatly reduces autoubiquitination activity; in isoform 1.
34	slightly reduces autoubiquitination activity; in isoform 1.
37	slightly reduces autoubiquitination activity; in isoform 1.
44	slightly reduces autoubiquitination activity; in isoform 1.
51	greatly reduces autoubiquitination activity; in isoform 1.
53	greatly reduces autoubiquitination activity; in isoform 1.
56	greatly reduces autoubiquitination activity; in isoform 1.
58	slightly reduces autoubiquitination activity; in isoform 1.
59	greatly reduces autoubiquitination activity; in isoform 1.
73	greatly reduces autoubiquitination activity; in isoform 1.
76	greatly reduces autoubiquitination activity; in isoform 1.

Function

Pathways and Gene Ontology

Reactome pathways

47 pathways

ID	Pathway
R-HSA-141430	Inactivation of APC/C via direct inhibition of the APC/C complex
R-HSA-174048	APC/C:Cdc20 mediated degradation of Cyclin B
R-HSA-174084	Autodegradation of Cdh1 by Cdh1:APC/C
R-HSA-174154	APC/C:Cdc20 mediated degradation of Securin
R-HSA-174178	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
R-HSA-174184	Cdc20:Phospho-APC/C mediated degradation of Cyclin A
R-HSA-176407	Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
R-HSA-176408	Regulation of APC/C activators between G1/S and early anaphase
R-HSA-176409	APC/C:Cdc20 mediated degradation of mitotic proteins
R-HSA-176412	Phosphorylation of the APC/C
R-HSA-179409	APC-Cdc20 mediated degradation of Nek2A
R-HSA-2467813	Separation of Sister Chromatids
R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)
R-HSA-68867	Assembly of the pre-replicative complex
R-HSA-69017	CDK-mediated phosphorylation and removal of Cdc6
R-HSA-8853884	Transcriptional Regulation by VENTX
R-HSA-9687136	Aberrant regulation of mitotic exit in cancer due to RB1 defects
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-141405	Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-168256	Immune System
R-HSA-174143	APC/C-mediated degradation of cell cycle proteins
R-HSA-176814	Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
R-HSA-179419	APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
R-HSA-212436	Generic Transcription Pathway
R-HSA-2262752	Cellular responses to stress
R-HSA-2555396	Mitotic Metaphase and Anaphase
R-HSA-2559583	Cellular Senescence

MSigDB gene sets: 203 (showing top): GOBP_CHROMOSOME_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_NUCLEAR_DIVISION, REACTOME_DNA_REPLICATION, REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1, REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B, REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE, REACTOME_PHOSPHORYLATION_OF_THE_APC_C, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_NUCLEAR_DIVISION, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_ANAPHASE_PROMOTING_COMPLEX_DEPENDENT_CATABOLIC_PROCESS, REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE

GO Biological Process (14): mitotic cell cycle (GO:0000278), ubiquitin-dependent protein catabolic process (GO:0006511), regulation of mitotic cell cycle (GO:0007346), protein ubiquitination (GO:0016567), anaphase-promoting complex-dependent catabolic process (GO:0031145), positive regulation of mitotic metaphase/anaphase transition (GO:0045842), cell division (GO:0051301), regulation of meiotic cell cycle (GO:0051445), protein K48-linked ubiquitination (GO:0070936), protein K11-linked ubiquitination (GO:0070979), protein branched polyubiquitination (GO:0141198), SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), obsolete proteolysis involved in protein catabolic process (GO:0051603)

GO Molecular Function (8): G protein-coupled receptor binding (GO:0001664), ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin-ubiquitin ligase activity (GO:0034450), ubiquitin protein ligase activity (GO:0061630), cullin family protein binding (GO:0097602), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), anaphase-promoting complex (GO:0005680), nucleolus (GO:0005730), cytosol (GO:0005829), cytoplasm (GO:0005737), cullin-RING ubiquitin ligase complex (GO:0031461)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
APC/C-mediated degradation of cell cycle proteins	4
APC/C:Cdc20 mediated degradation of mitotic proteins	2
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	2
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	2
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	1
Mitotic Anaphase	1
Cellular Senescence	1
DNA Replication Pre-Initiation	1
Switching of origins to a post-replicative state	1
Generic Transcription Pathway	1
Aberrant regulation of mitotic cell cycle due to RB1 defects	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Regulation of APC/C activators between G1/S and early anaphase	1
Mitotic Spindle Checkpoint	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein polyubiquitination	3
cellular anatomical structure	3
regulation of cell cycle	2
proteasome-mediated ubiquitin-dependent protein catabolic process	2
nuclear lumen	2
cell cycle	1
mitotic nuclear division	1
protein ubiquitination	1
modification-dependent protein catabolic process	1
mitotic cell cycle	1
protein modification by small protein conjugation	1
metaphase/anaphase transition of mitotic cell cycle	1
regulation of mitotic metaphase/anaphase transition	1
positive regulation of mitotic nuclear division	1
positive regulation of mitotic sister chromatid separation	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of metaphase/anaphase transition of cell cycle	1
cellular process	1
meiotic cell cycle	1
regulation of reproductive process	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
signaling receptor binding	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin protein ligase activity	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
protein binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear ubiquitin ligase complex	1
cullin-RING ubiquitin ligase complex	1
intracellular membraneless organelle	1
cytoplasm	1
intracellular anatomical structure	1
ubiquitin ligase complex	1

Protein interactions and networks

STRING

1530 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANAPC11	ANAPC10	Q9UM13	998
ANAPC11	CDC20	Q12834	989
ANAPC11	ANAPC5	Q9UJX4	979
ANAPC11	CDC23	Q9UJX2	979
ANAPC11	CDC27	P30260	932
ANAPC11	CDC26	Q8NHZ8	923
ANAPC11	CDC16	Q13042	920
ANAPC11	ANAPC2	Q9UJX6	910
ANAPC11	RBX1	P62877	894
ANAPC11	UBE2S	Q16763	889
ANAPC11	ANAPC13	Q9BS18	877
ANAPC11	RNF7	Q9UBF6	872
ANAPC11	ANAPC16	Q96DE5	842
ANAPC11	ANAPC15	P60006	834
ANAPC11	ANAPC4	Q9UJX5	797

IntAct

35 interactions, top by confidence:

A	B	Type	Score
ANAPC2	CDC27	psi-mi:“MI:0915”(physical association)	0.910
ANAPC4	CDC27	psi-mi:“MI:0914”(association)	0.860
ANAPC2	BUB1B	psi-mi:“MI:0914”(association)	0.730
Cdc23	BUB1B	psi-mi:“MI:0915”(physical association)	0.560
Cdc16	BUB1B	psi-mi:“MI:0915”(physical association)	0.560
GRN	ANAPC11	psi-mi:“MI:0915”(physical association)	0.560
ANAPC11	PEX1	psi-mi:“MI:0915”(physical association)	0.560
SLC35B1	PGRMC1	psi-mi:“MI:0914”(association)	0.530
UBE2U	ANAPC11	psi-mi:“MI:0915”(physical association)	0.370
ANAPC11	MAK	psi-mi:“MI:0915”(physical association)	0.370
ANAPC11	ZAP70	psi-mi:“MI:0915”(physical association)	0.370
CAPN11	ANAPC11	psi-mi:“MI:0915”(physical association)	0.370
MLKL	ANAPC11	psi-mi:“MI:0915”(physical association)	0.370
ANAPC11	NKD2	psi-mi:“MI:0915”(physical association)	0.370
ANAPC11	RNF111	psi-mi:“MI:0915”(physical association)	0.370
ANAPC11	TRIM65	psi-mi:“MI:0915”(physical association)	0.370
CDC16	BUB3	psi-mi:“MI:0914”(association)	0.350
ANAPC11	CCT7	psi-mi:“MI:0914”(association)	0.350
ANAPC4	BUB1	psi-mi:“MI:0914”(association)	0.350

BioGRID (257): ANAPC11 (Reconstituted Complex), ANAPC11 (Co-crystal Structure), ANAPC11 (Affinity Capture-MS), ANAPC11 (Biochemical Activity), UBE2S (Reconstituted Complex), UBE2D1 (Reconstituted Complex), UBE2C (Reconstituted Complex), UBE2C (Reconstituted Complex), UBE2K (Reconstituted Complex), UBE2C (Reconstituted Complex), UBE2K (Reconstituted Complex), UBE2D2 (Reconstituted Complex), UBE2C (Reconstituted Complex), PTTG1 (Biochemical Activity), UBE2S (Reconstituted Complex)

ESM2 similar proteins: A7S7Z9, A9SY65, E0X9N4, E5KGE0, G5EDR3, O01965, O14099, O76924, O80996, O95376, P0C8K8, P87141, Q04673, Q08273, Q22431, Q29IK8, Q3ZCF6, Q54KR5, Q54L48, Q5JL96, Q5NU13, Q5R8A2, Q5ZA07, Q6IDS6, Q84RR0, Q8L829, Q8W468, Q95QN6, Q96PM5, Q99MP8, Q9CPX9, Q9DD48, Q9DFG8, Q9ERV1, Q9H000, Q9JI90, Q9M9L0, Q9N373, Q9NHX0, Q9NYG5

Diamond homologs: O13959, P62877, P62878, Q08273, Q20052, Q23457, Q3ZCF6, Q54K33, Q54L48, Q5R8A2, Q5UQ40, Q7X843, Q8BGI1, Q8QG64, Q940X7, Q9CPX9, Q9M2B0, Q9M9L0, Q9NHX0, Q9NYG5, Q9UBF6, Q9W5E1, Q9WTZ1, Q9Y225, O74757, P0C041, Q08CG8, Q12157, Q9LF64, O22755, Q8W571, Q9LZJ6, Q9LZV8, Q9SG96, Q9SRQ8, Q9UT86, Q9ZT49, Q6AXU4, Q5XF85, Q67YI6

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	ANAPC11	ubiquitination
ANAPC11	“form complex”	APC-c	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	7	193.1×	2e-13
Inactivation of APC/C via direct inhibition of the APC/C complex	7	158.0×	6e-13
APC-Cdc20 mediated degradation of Nek2A	7	128.7×	2e-12
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	7	128.7×	2e-12
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	7	124.1×	2e-12
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase	5	112.8×	6e-09
APC/C:Cdc20 mediated degradation of mitotic proteins	7	108.6×	4e-12
APC/C-mediated degradation of cell cycle proteins	7	102.2×	5e-12

GO biological processes:

GO term	Partners	Fold	FDR
regulation of meiotic cell cycle	5	147.3×	2e-08
anaphase-promoting complex-dependent catabolic process	5	135.0×	2e-08
regulation of mitotic cell cycle	5	46.3×	2e-06
protein K48-linked ubiquitination	5	32.4×	9e-06
cell division	8	14.2×	2e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1033 predictions. Top by Δscore:

Variant	Effect	Δscore
17:81890684:CTTAC:C	donor_loss	1.0000
17:81890686:TACC:T	donor_loss	1.0000
17:81890687:A:AC	donor_gain	1.0000
17:81890687:ACCT:A	donor_loss	1.0000
17:81890688:C:CC	donor_gain	1.0000
17:81890816:TTTGG:T	acceptor_gain	1.0000
17:81890817:TTGG:T	acceptor_gain	1.0000
17:81890818:TGG:T	acceptor_gain	1.0000
17:81890818:TGGC:T	acceptor_loss	1.0000
17:81890819:GG:G	acceptor_gain	1.0000
17:81890820:GCTGA:G	acceptor_loss	1.0000
17:81890821:C:CC	acceptor_gain	1.0000
17:81890834:C:CT	acceptor_gain	1.0000
17:81890834:C:T	acceptor_gain	1.0000
17:81891319:TCA:T	donor_loss	1.0000
17:81891320:CAC:C	donor_loss	1.0000
17:81891321:A:AC	donor_gain	1.0000
17:81891321:AC:A	donor_gain	1.0000
17:81891322:C:CC	donor_gain	1.0000
17:81891322:CC:C	donor_gain	1.0000
17:81891322:CCCTG:C	donor_gain	1.0000
17:81894587:G:GG	donor_gain	1.0000
17:81891321:ACC:A	donor_gain	0.9900
17:81891322:CCC:C	donor_gain	0.9900
17:81891322:CCCT:C	donor_gain	0.9900
17:81891762:G:GT	donor_gain	0.9900
17:81891825:G:GT	donor_gain	0.9900
17:81894583:GACT:G	donor_gain	0.9900
17:81890685:TTA:T	donor_gain	0.9800
17:81890686:TAC:T	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000030905 (17:81895528 G>A), RS1000144064 (17:81892449 A>G), RS1000204782 (17:81898742 AGTTTTAATTTAAAAAAAT>A), RS1000262493 (17:81893374 G>A,C), RS1000372449 (17:81898394 A>G,T), RS1000428640 (17:81892765 C>T), RS1000477458 (17:81890958 G>A), RS1000631811 (17:81896721 G>A,C), RS1000701691 (17:81897908 G>A,T), RS1000746761 (17:81898190 T>C), RS1001531998 (17:81890257 T>C), RS1001635435 (17:81893103 G>C), RS1001842265 (17:81892257 C>A), RS1001937175 (17:81892134 C>A,G,T), RS1001973817 (17:81891825 G>T)

Disease associations

OMIM: gene MIM:614534 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196123 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
dicrotophos	decreases expression	1
lasiocarpine	increases expression, increases metabolic processing	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
bisphenol A	decreases expression	1
beta-lapachone	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Bortezomib	decreases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Chelating Agents	decreases expression, affects binding	1
Copper	affects binding, decreases expression	1
Doxorubicin	increases expression	1
Estradiol	decreases expression	1
Gallic Acid	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Ozone	affects cotreatment, increases expression, increases abundance	1
Smoke	decreases expression	1
Tretinoin	increases expression	1
Tunicamycin	decreases expression	1
Valproic Acid	affects cotreatment, increases expression	1
Cyclosporine	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6114788	Binding	Binding affinity to APC11 (unknown origin) assessed as binding free energy	De Novo-Designed APC/C Inhibitors Provide a Rationale for Targeting RING-Type E3 Ubiquitin Ligases. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.